Oss, Netherlands

Aartje Maria Elizabeth Veraar

USPTO Granted Patents = 1 


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Aartje Maria Elizabeth Veraar: Innovator in Antibody Technology

Introduction

Aartje Maria Elizabeth Veraar is an accomplished inventor based in Oss, Netherlands. With a remarkable focus on biotechnology, she has contributed significantly to the field of immunology through her innovative work. Her dedication to scientific research has led to the development of a patent that holds potential for advancements in therapeutic applications.

Latest Patents

Aartje Veraar is credited with one patent: an agonistic antibody to CD27. This invention concerns a binding compound that targets the same epitope of human CD27 as the monoclonal antibody hCD27.15. The hybridoma hCD27.15 was deposited with the ATCC on June 2, 2010, under number PTA-11008. The binding compound may include an antibody heavy chain variable region featuring at least one CDR from the specified group, alongside a light chain variable region possibly containing CDRs as well, ensuring a versatile approach toward antibody design.

Career Highlights

Aartje Veraar currently works at Aduro Biotech Holdings, Europe B.V., where she continues to push the boundaries of antibody research. Her expertise in binding compounds not only highlights her innovative capabilities but also her commitment to developing solutions for complex medical challenges. Aartje's patent represents a significant contribution to the ongoing advancements in antibody therapies.

Collaborations

Throughout her career, Aartje has collaborated with esteemed colleagues including Hans Van Eenennaam and Winfried Robert Mulder. These partnerships have fostered a collaborative environment that encourages creativity and knowledge sharing, which is essential for driving innovation in their field.

Conclusion

Aartje Maria Elizabeth Veraar exemplifies how dedication to research and innovation can culminate in groundbreaking inventions. Her work on the agonistic antibody to CD27 has the potential to influence the future of therapeutic research and development. As she continues her journey in the biotechnology sector, there is no doubt that her contributions will leave a lasting impact on the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…